Valuation: GlucoTrack, Inc.

Market Cap 1.47M 1.27M 1.2M 1.09M 2.05M 141M 2.06M 14.38M 5.53M 71.53M 5.52M 5.4M 228M P/E 2024 *
-
P/E 2025 -0.12x
Enterprise Value -2.47M -2.14M -2.02M -1.83M -3.43M -237M -3.46M -24.11M -9.27M -120M -9.26M -9.06M -383M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
89.8%
Yield 2024 *
-
Yield 2025 -
1 day-7.35%
1 week-23.83%
Current month-46.59%
1 month-58.81%
3 months-60.84%
6 months-87.49%
Current year-96.09%
1 week 2.22
Extreme 2.22
3.3
1 month 2.22
Extreme 2.22
6.07
Current year 2.22
Extreme 2.22
63.6
1 year 2.22
Extreme 2.22
136.29
3 years 2.22
Extreme 2.22
89,100.09
5 years 2.22
Extreme 2.22
567,000.57
10 years 2.22
Extreme 2.22
7,020,007.02
Manager TitleAgeSince
Chief Executive Officer 55 2026-07-13
Director of Finance/CFO 66 2025-01-27
Chief Operating Officer - 2025-01-31
Director TitleAgeSince
Director/Board Member 59 2024-08-26
Director/Board Member 56 2023-08-24
Chairman 64 2024-02-12
Date Insider Type Main position Quantity % Market Cap. Importance
3/26/25 Free

Director

4,490 0.0431%
3/25/25 Free

Director

8,747 0.0840%
3/25/25 Free

Director

5,473 0.0526%
Change 5-day change 1-year change 3-year change Capi.($)
-7.35%-23.83%-98.57%-99.99% 1.02M
+0.56%-4.17%-1.90%+9.79% 45.63B
-0.12%-2.46%+340.09%+529.37% 43.96B
+1.51%+0.71%+44.04%+26.63% 43.73B
-2.07%-3.28%+6.83%+74.56% 40.23B
-0.73%-4.72%+8.55%+37.89% 31.86B
-9.49%-11.38% - - 17.4B
+4.21%+4.94%+26.46%+121.58% 16.62B
+1.83%+2.63%+15.14%+33.31% 14.46B
-0.08%-5.41%+78.48%+31.34% 13.04B
Average -1.19%-3.41%+46.57%+84.94% 26.69B
Weighted average by Cap. -0.36%-2.09%+76.22%+128.25%

Financials

2024 2025
Net sales - -
Net income -22.6M -19.57M -18.51M -16.76M -31.45M -2.17B -31.69M -221M -84.98M -1.1B -84.88M -83M -3.51B -19.39M -16.79M -15.88M -14.38M -26.98M -1.86B -27.19M -190M -72.91M -943M -72.83M -71.21M -3.01B
Net Debt -5.35M -4.63M -4.38M -3.97M -7.45M -513M -7.5M -52.29M -20.12M -260M -20.1M -19.65M -830M -3.94M -3.41M -3.22M -2.92M -5.48M -378M -5.52M -38.48M -14.81M -191M -14.79M -14.46M -611M
Logo GlucoTrack, Inc.
Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
Employees
15
Date Price Change Volume
26-09-15 US$2.270 -7.35% 55,505
26-09-14 US$2.450 -3.92% 153,084
26-09-11 US$2.550 -21.05% 744,247
26-09-10 US$3.230 +2.87% 17,700
26-09-09 US$3.140 +7.17% 59,005
  1. Stock Market
  2. Stocks
  3. GCTK Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!